ANRO Stock Forecast & Price Target

Alto Neuroscience has demonstrated substantial revenue growth, with FY24 revenue reaching $1.08 billion, marking a 60% increase from the previous year. The company's clinical assets, such as SLS-002 and SPRAVATO, exhibited significant efficacy improvements in treating mood disorders, including a 3.3-point improvement in the MADRS scale for SLS-002 at 24 hours and notable gains observed in long-term studies for TRD patients. Furthermore, the acquisition of ALTO-207 and advancements in treatment administration, supported by positive data on dose-dependent effects and improved safety profiles, position Alto Neuroscience favorably for continued growth and market expansion.

Alto Neuroscience's stock outlook appears negative due to the significant setback experienced with ALTO-100's failure in major depressive disorder (MDD), highlighting potential fundamental issues in the company's drug development process. Management has indicated that non-compliance with study drug in specific patient groups may have further exacerbated treatment outcomes, raising concerns about the reliability of their clinical data. Additionally, research findings suggest that cognitive deficits and reduced neuroplasticity in target patient populations could undermine the efficacy of their treatment options, posing challenges for future asset viability and market acceptance.